INVENTIVA
FREURINVENTIVA (PA:IVA) — Biotechnology. Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- inventivapharma.com
- Sektor
- Healthcare · Biotechnology
- Hovedkontor
- Daix, France
- Administrerende Direktør
- Andrew Obenshain
- Ansatte
- 87
- Udestående Aktier
- 236.22 mio.
- Free Float
- 165.57 mio.
- Markedsværdi
- 711.02 mio. EUR
- Insidere
- 12.63%
- Institutionelle Investorer
- 50.05%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk Form
- K65D
- ISIN
- FR0013233012
- LEI
- 969500I9Y690B3FZW590
Beskrivelse
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Caligan Partners, LP | 3.91% | 8.16 mio. | 2026-06-30 |
| Samsara BioCapital, LLC | 3.02% | 6.31 mio. | 2026-06-30 |
| Paradigm Biocapital Advi… | 1.91% | 4 mio. | 2026-06-30 |
| Andera Partners | 1.74% | 3.63 mio. | 2026-06-30 |
| Adar1 Capital Management… | 1.73% | 3.61 mio. | 2026-06-30 |
| Millennium Management Ll… | 1.68% | 3.51 mio. | 2026-06-30 |
| Nantahala Capital Manage… | 1.29% | 2.69 mio. | 2026-06-30 |
| Trails Edge Capital Part… | 1.27% | 2.66 mio. | 2026-06-30 |
| Franklin Resources, Inc. | 1.26% | 2.64 mio. | 2026-06-30 |
| Squadron Capital Managem… | 1.17% | 2.44 mio. | 2026-06-30 |
| abrdn World Healthcare F… | 0.58% | 1.21 mio. | 2026-06-30 |
| abrdn Life Sciences Inve… | 0.52% | 1.09 mio. | 2026-06-30 |
| Franklin Strategic Serie… | 0.49% | 1.01 mio. | 2026-07-31 |
| Fidelity Advisor Series… | 0.33% | 685 400 | 2026-07-31 |
| Artisan Partners Funds I… | 0.27% | 637 859 | 2026-06-30 |
| Simplify Exchange Traded… | 0.15% | 313 483 | 2026-06-30 |
| Fidelity Concord Street… | 0.07% | 154 400 | 2026-07-31 |
| Fidelity Concord Street… | 0.07% | 136 161 | 2026-07-31 |
| Fidelity Rutland Square… | 0.03% | 63 678 | 2026-07-31 |
| Blackstone Alternative I… | 0.02% | 42 752 | 2026-06-30 |
| Fidelity Concord Street… | 0.01% | 29 300 | 2026-07-31 |
| -SSgA SPDR ETFS Europe I… | 0.01% | 16 409 | 2026-07-31 |
| -SSgA SPDR ETFS Europe I… | 0% | 9 843 | 2026-07-31 |
| -SSgA SPDR ETFS Europe I… | 0% | 3 704 | 2026-07-31 |
| DBX ETF Trust-Xtrackers… | 0% | 1 327 | 2026-05-31 |
| -Goldman Sachs MSCI Worl… | 0% | 301 | 2026-08-31 |
